SYS-CON MEDIA Authors: Jason Bloomberg, Sandi Mappic, RealWire News Distribution, Kevin Benedict, Bob Gourley

News Feed Item

North American Pharma-Biotech Sector to Wrap Up Construction on 116 Projects Worth $3.7 Billion in Second-Quarter 2014, an Industrial Info News Alert

SUGAR LAND, TX -- (Marketwired) -- 05/12/14 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Midway through the second quarter of 2014, the North American Pharmaceutical-Biotech Industry is busy finishing out an impressive array of capital construction projects. With roughly a month and a half left to the quarter, the sector is on target to complete construction on 116 North American capital projects, each as diverse as the industry itself. A recent survey of reported projects in Industrial Info's Pharmaceutical Biotech Tracker-Online Database reveals that the projects represent a total investment value (TIV) of $3.7 billion.

Other companies featured: Novartis AG (NYSE:NVS), Sanofi (NYSE:SNY)

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/news/abstract.jsp?newsitemID=242032&refer=mw, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle¬ô, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the www.industrialinfo.com "Contact Us" page.

Contact:
Joe Govreau
713-783-5147

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.